The Prevalence of Barrett Esophagus Diagnosed in the Second Endoscopy

Suna, Nuretdin; Parlak, Erkan; Kuzu, Ufuk Barış; Yıldız, Hakan; Köksal, Aydın Şeref; Öztaş, Erkin; Sırtaş, Zeliha; Yüksel, Mahmut; Aydinli, Onur; Bilge, Zülfikar; Taşkıran, İsmail; Şaşmaz, Nurgül

doi:10.1097/md.0000000000003313

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, additional data on the detection of BE at endoscopic evaluation performed at longer intervals after an initial negative screening endoscopy would better clarify long-term risks. In another smaller retrospective study from Turkey, only 0.66% of 2,701 patients undergoing repeat endoscopy within 6 years of an initial negative examination had BE on the second endoscopy (71). In addition, the ProGERD study was a prospective cohort study of reflux patients under treatment with proton pump inhibitor (PPI) who underwent endoscopy at enrollment and again 5 years later.…”

Section: Recommendationmentioning

confidence: 99%

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

et al. 2022

View full text Add to dashboard Cite

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.

show abstract

Section: Recommendationmentioning

confidence: 99%

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They were published between 1985 and 2022. Sixteen studies were performed in Asia, 19 – 34 16 in Europe, 35 – 50 14 in America, 51 – 64 and 1 in Oceania. 65 …”

Section: Resultsmentioning

confidence: 99%

Association between hiatal hernia and Barrett’s esophagus: an updated meta-analysis with trial sequential analysis

Ma,

Tong,

et al. 2024

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Barrett’s esophagus (BE) is a precursor of esophageal adenocarcinoma. It is critical to recognize the risk factors associated with BE. Objectives: The present meta-analysis aims to systematically estimate the association of hiatal hernia with the risk of BE. Design: A meta-analysis with trial sequential analysis. Data sources and methods: The PubMed, EMBASE, and Cochrane Library databases were searched. The pooled odds ratios (ORs) and adjusted ORs (aORs) with their 95% confidence intervals (CIs) were calculated for the combined estimation of unadjusted data and data adjusted for confounders, respectively. Heterogeneity was quantified using the Cochrane Q test and I² statistics. Subgroup, meta-regression, and leave-one-out sensitivity analyses were employed to explore the sources of heterogeneity. Results: Forty-seven studies with 131,517 participants were included. Based on the unadjusted data from 47 studies, hiatal hernia was significantly associated with an increased risk of any length BE (OR = 3.91, 95% CI = 3.31–4.62, p < 0.001). The heterogeneity was significant ( I² = 77%; p < 0.001) and the definition of controls ( p = 0.014) might be a potential contributor to heterogeneity. Based on the adjusted data from 14 studies, this positive association remained (aOR = 3.26, 95% CI = 2.44–4.35, p < 0.001). The heterogeneity was also significant ( I² = 65%; p < 0.001). Meta-analysis of seven studies demonstrated that hiatal hernia was significantly associated with an increased risk of long-segment BE (LSBE) (OR = 10.01, 95% CI = 4.16–24.06, p < 0.001). The heterogeneity was significant ( I² = 78%; p < 0.001). Meta-analysis of seven studies also demonstrated that hiatal hernia was significantly associated with an increased risk of short-segment BE (OR = 2.76, 95% CI = 2.05–3.71, p < 0.001). The heterogeneity was not significant ( I² = 30%; p = 0.201). Conclusion: Hiatal hernia should be a significant risk factor for BE, especially LSBE. Registration: PROSPERO registration number CRD42022367376.

show abstract